ESMO 2021 Videos

Cabazitaxel as a Third-Line Treatment After Docetaxel and an Androgen Receptor Targeting Agent in mCRPC Patients – Alicia Morgans

Enzalutamide Plus Talazoparib vs Placebo Plus Enzalutamide in Men With DDR Gene Mutations, the TALAPRO-3 Trial in mCSPC – Neeraj Agarwal

Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde

Preliminary Results of MGC018, an anti B7-H3 Antibody Drug Conjugate in mCRPC – Eugene Shenderov

Tazemetostat in Combination With Abiraterone + Prednisone or Enzalutamide in mCRPC – Wassim Abida

Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors CABA-GCT - Giulia Baciarello

Prospective Analysis of The Effect of Germline Mutations on Outcomes for mCRPC Patients Treated With Radium-223 (PRORADIUM) – Elena Castro

CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak

Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky

Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski

Time Course Profile of Adverse Events With Darolutamide in the ARAMIS Trial – Christian Gratzke

Cognitive Assessment in Men with Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial - Karim Fizazi

Darolutamide Maintenance in mCRPC Previously Treated with Novel Hormonal Agents - Richard Cathomas

Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer – Ravi Madan

PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris

COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal

First-in-Human Study of FOR46 in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) – Rahul Aggarwal

Pain and Symptomatic Skeletal Events Reported in the VISION Trial – Oliver Sartor

Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma – Giuseppe Procopio

Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer

STAMPEDE Analysis of Abiraterone With or Without Enzalutamide Added to Androgen Deprivation Therapy Compared to ADT Alone In High-Risk Non-Metastatic Prostate Cancer Patients– Gerhardt Attard

Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Scott Tagawa

Combined Testosterone Therapy with Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer – Michael Schweizer

Relugolix in the Phase 3 HERO Study in Men with mHSPC - Bertrand Tombal

Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo mCSPC – Karim Fizazi

Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi

Radiopharmaceuticals in Prostate Cancer: A Deep Dive into Patient-Reported Outcomes - Scott Tagawa

PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor